Rna guided eradication of herpes simplex type i and other related herpesviruses
AssigneeTemple University - Of The Commonwealth System of Higher Eduction
InventorsPamela C. Roehm, Kamel Khalili, Sayed Masoud Shekarabi, Hassen Wollebo
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the inhibition of the infectivity of a herpesvirus. In certain embodiments, the compositions and methods provide a CRISPR-associated peptide and a guide nucleic acid, which induce the mutation of herpesvirus genome, thereby inhibiting the infectivity of the herpesvirus. Further disclosed are Cas peptides including Cas9 or a variant thereof comprising one or more point mutations relative to wildtype Streptococcus pyogenes Cas 9 (spCas9), and Cpf1 or a variant thereof.
Claims26
A composition for treating or preventing a herpesvirus infection comprising:
- a) one selected from the group consisting of a CRISPR-associated (Cas) peptide and an isolated nucleic acid encoding a Cas peptide;
- and
- b) one selected from the group consisting of an isolated guide nucleic acid and an isolated nucleic acid encoding a guide nucleic acid, where the guide nucleic acid comprises a nucleotide sequence substantially complementary to a target sequence in the herpesvirus genome.
A pharmaceutical composition comprising
- a) one selected from the group consisting of a CRISPR-associated (Cas) peptide and an isolated nucleic acid encoding a Cas peptide;
- and
- b) one selected from the group consisting of an isolated guide nucleic acid and an isolated nucleic acid encoding a guide nucleic acid, where the guide nucleic acid comprises a nucleotide sequence substantially complementary to a target sequence in the herpesvirus genome.
An expression vector encoding a CRISPR-associated (Cas) peptide and a guide nucleic acid, wherein the a guide nucleic acid comprises a nucleotide sequence substantially complementary to a target sequence in the herpesvirus genome.
A method of treating or preventing a herpesvirus infection or herpesvirus-associated disorder in a subject, the method comprising contacting a cell of the subject with a therapeutically effective amount of a composition comprising
- a) one selected from the group consisting of a CRISPR-associated (Cas) peptide and an isolated nucleic acid encoding a Cas peptide;
- and
- b) one selected from the group consisting of an isolated guide nucleic acid and an isolated nucleic acid encoding a guide nucleic acid, where the guide nucleic acid comprises a nucleotide sequence substantially complementary to a target sequence in the herpesvirus genome.
Dependencies are inferred from the claim text.